DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Peter Verdult - 6 Eli Lilly - 5 Lilly - 4 Wegovy - 3 — CNBC's Michael Bloom - 3 Verdult - 3 Morgan Stanley - 2 Michael Bloom - 2
Top related locs:
U.S GLP DaVita ResMed Chicago , Illinois Danish Europe London
Top related orgs:
Novo Nordisk - 5 Citi - 5 Novo - 3 JPMorgan - 2 UBS - 2 Deutsche Bank - 2 GLP - 2 Bank of America - 2

Search resuls for: "Peter Verdult"


8 mentions found


☆ Here's what Wall Street is saying about obesity drug Wegovy following Novo Nordisk's key study
  + stars: | 2023-11-13 | by ( Alex Harring | ) www.cnbc.com   time to read: +6 min
Wegovy contains semaglutide, the same active ingredient in Novo's type 2 diabetes drug Ozempic. A rising tide for Eli Lilly? Though the study was specifically about Wegovy, Wall Street sees a positive readthrough for similar medications from other providers, particularly Eli Lilly 's Zepbound. Similarly, UBS analyst Trung Huynh called the weekend data a "best-case" scenario for Eli Lilly. And the positive outcomes for both in the Wegovy study can be viewed as encouraging for how Zepbound should perform, the analyst added.
Persons: Morgan Stanley, Mark Purcell, Richard Vosser, Peter Verdult, Eli Lilly, Eli Lilly's, Lilly, Andrew Baum, Trung Huynh, That's, it's, Zepbound, Huynh, Citi's Baum, James Shin isn't, Michael Bloom, Christina Cheddar Berk, Angelica Peebles Organizations: Novo Nordisk, American Heart Association, cardiologists, JPMorgan, Citi, ., UBS, North American, Tandem Diabetes Care, Deutsche Bank
☆ Ride the weight loss drug wave with this gym stock set to nearly double, says Evercore ISI
  + stars: | 2023-10-17 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
Planet Fitness shares could soar as new weight loss drugs become popular and users flock to the gym, according to Evercore ISI. Shares of Planet Fitness have dropped about 30% in 2023, plunging 16% in a single day last month when the company announced the surprise ousting of CEO Chris Rondeau . Although GLP-1 drugs aid weight loss by suppressing appetite, it's still essential for patients to adopt healthy habits for long-term success. This is a positive development for Planet Fitness, resulting in a rush of new gym memberships, Cheng said. He estimated that one million new members would amount to roughly 15% upside in earnings per share for Planet Fitness by 2025.
Persons: Warren Cheng, Evercore, Chris Rondeau, Cheng, Citi's Peter Verdult, —, Christina Cheddar, Berk, Michael Bloom Organizations: Fitness, ISI, GLP, Planet Fitness, Planet
☆ Which stocks might be disrupted next by Ozempic and other GLP-1 drugs
  + stars: | 2023-10-12 | by ( Christina Cheddar Berk Samantha Subin | Christina Cheddar Berk | Samantha Subin | ) www.cnbc.com   time to read: +11 min
How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.
Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed
☆ Bank of America sees risks for employers as insurance coverage of weight loss drugs grows
  + stars: | 2023-10-11 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +4 min
The eye-popping predictions for weight loss drug sales hinge on insurance companies agreeing to provide coverage of the pricey treatments, and momentum seems to be building on that front. The drugs include Novo Nordisk's semaglutide, which is sold as Ozempic for diabetes management and as Wegovy for weight loss. Unlike earlier generations of weight loss medicines, their side effects have been largely mild and included diarrhea, constipation and nausea. Higher hospital labor costs as well as GLP-1 medications are contributing to the biggest jump in health insurance costs since 2012, Lutz said. But those numbers will grow, especially as ongoing research continues to make the case for benefits beyond blood sugar control and weight loss.
Persons: Allen Lutz, Lutz, Lutz's, Savanta, Accolade, Eli Lilly, Mercer, Willis Towers Watson, Peter Verdult, Verdult, — CNBC's Michael Bloom Organizations: Bank of America, Accolade, Novo Nordisk's semaglutide, Food, Drug Administration, Citi, Nordisk, Centers for Disease Control Locations: U.S
☆ Obesity drug Wegovy's landmark trial result could 'open up' health insurance access, analyst says
  + stars: | 2023-08-09 | by ( Karen Gilchrist | ) www.cnbc.com   time to read: +6 min
Until now, some health insurers have been reluctant to cover the drug, given its high costs and a lack of data around its underlying health benefits. But the results of the latest trial data could change that. "Do I think most payers will adopt [obesity drugs] overnight because of the SELECT trial? According to the World Health Organization, global obesity rates have almost tripled over the past decade. Novo Nordisk shares soared by 17% following the release of the trial results on Tuesday.
Persons: Jim Vondruska, Peter Verdult, CNBC's, Wegovy, Verdult, Martin Holst Lange, Eli Lilly, Mounjaro, Michael Mason, Eli Lily, Lilly Diabetes, It's, Lilly, Novo, Lily Organizations: Reuters LONDON, Novo Nordisk, Citi, Novo, World Health Organization, Barclays, Citi Verdult, European Markets Authority Locations: Chicago , Illinois, Danish, U.S, Europe, London
☆ U.S. doctors are 'wowed' by Novo Nordisk's weight-loss drug data, analyst says
  + stars: | 2023-08-09 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailU.S. doctors are 'wowed' by Novo Nordisk's weight-loss drug data, analyst saysPeter Verdult, managing director of Citi Pharma Research Citigroup, discusses the findings of Novo Nordisk 's closely watched "SELECT" trial.
Persons: Peter Verdult Organizations: Novo, Citi Pharma Research Citigroup, Novo Nordisk
☆ What investors need to know about weight loss medicines and suicide risk
  + stars: | 2023-07-16 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +7 min
Investors would be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week. Prior attempts to treat overweight or obese patients with medications were often plagued with side effects and drug recalls. The first is that most obesity drugs, including GLP-1s, are "centrally acting," which means they work on a patient's brain. The second is that prior obesity drugs have been withdrawn because of high rates of psychiatric disorders, he said, citing Sanofi's Acomplia as one of the more recent examples. This was not the case for the GLP-1 medications.
Persons: skittishness, Eli Lilly's Trulicity, Lilly's, Wolfe, Tim Anderson, Anderson, Sanofi's Acomplia, Eli Lilly, Wolfe's Anderson, Colin Bristow, Lilly, LLY's, Peter Verdult, Wegovy, Verdult, Bristow, Emmanuel Papadakis, Papadakis, — CNBC's Michael Bloom Organizations: Nordisk's Ozempic, Wall Street, European Medicines Agency, EMA, Wolfe Research, FDA, UBS, Citi, Novo Nordisk, Deutsche Bank, Prevention Locations: United States, U.S
☆ 'Miracle' drugs could remake the weight loss industry
  + stars: | 2023-04-03 | by ( Julianna Tatelbaum | ) www.cnbc.com   time to read: +1 min
Wegovy is one of several new "miracle" drugs that promise to revolutionize the weight-loss industry. You're getting 15 to 17 approaching 20% weight loss with a weekly injection," Peter Verdult, a pharmaceuticals analyst at Citi, told CNBC. A report by the World Health Organization in 2022 showed that obesity has nearly tripled since 1975 and continues to rise. More than 1 billion people are clinically obese globally, of whom 650 million are adults, 340 million are adolescents and 39 million are children. But the long-term consequences of these drugs remain unknown.
0 next >>
Total: 8